文献速递心脑血管急症重症综合管理与镇静镇痛

重症COVID-19患者中的急性症状性癫痫发作:是否存在关联?

Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is There an Association?
PubMed 文献 · Neurocrit Care · 2021-01-01
一句话结论两例无癫痫史的重症COVID-19老年男性在住院期间出现临床和脑电图癫痫发作,左乙拉西坦治疗后发作缓解;作者认为有临床癫痫发作征象或不明原因脑病的患者可能受益于脑电图监测和/或经验性抗癫痫治疗。

本文报告两例来自美国俄亥俄州东北部医疗系统的老年、无癫痫史男性患者,2020年3月中旬因疑似感染就诊,均有肺病病史,住院期间SARS-CoV-2检测阳性。两人在住院数天后出现急性脑病,伴临床和脑电图癫痫发作,使用左乙拉西坦后发作缓解。作者讨论认为COVID-19患者癫痫发作风险升高,机制可能为多因素,包括细胞因子反应介导的血脑屏障破坏所致皮质刺激;由于镇静剂和肌松剂广泛使用及脑电图监测资源有限,临床(运动)发作可能不易被发现。作者结论认为有临床癫痫发作征象或不明原因脑病的患者可能受益于脑电图监测和/或经验性抗癫痫治疗,需进一步研究明确该人群癫痫发作风险和监测获益。

要点

  • 两例无癫痫史的老年男性重症COVID-19患者在住院数天后出现急性脑病,伴临床和脑电图癫痫发作。
  • 两例患者癫痫发作均经左乙拉西坦治疗后缓解。
  • 作者认为COVID-19患者癫痫发作风险升高,机制可能为多因素,包括细胞因子反应介导的血脑屏障破坏所致皮质刺激。
  • 作者指出因镇静剂和肌松剂广泛使用,临床(运动)癫痫发作在该人群中可能不易被发现。
  • 作者认为有临床癫痫发作征象或不明原因脑病的患者可能受益于脑电图监测和/或经验性抗癫痫治疗。

适用人群与场景

  • 两例老年、无癫痫史男性患者,均有肺病病史,2020年3月中旬因疑似感染就诊于美国俄亥俄州东北部医疗系统,住院期间SARS-CoV-2检测阳性。

处置流程与药物剂量

  • 两例患者癫痫发作使用左乙拉西坦治疗后缓解(原文未写明剂量、途径、频次)。

红旗征与不能漏的情况

  • 住院数天后出现急性脑病,伴临床和脑电图癫痫发作。
  • 作者指出因镇静剂和肌松剂广泛使用,临床(运动)癫痫发作在该人群中可能不易被发现。

研究设计与关键结果

  • 病例报告:两例老年、无癫痫史男性重症COVID-19患者,住院数天后出现急性脑病伴临床和脑电图癫痫发作,左乙拉西坦治疗后发作缓解。

证据类型、等级与局限

  • 证据类型:病例报告(两例)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为有临床癫痫发作征象或不明原因脑病的COVID-19患者可能受益于脑电图监测和/或经验性抗癫痫治疗。
  • 作者指出因镇静剂和肌松剂广泛使用及脑电图监测资源有限,临床(运动)癫痫发作在该人群中可能不易被发现。
  • 作者结论认为需进一步研究明确该人群癫痫发作风险和监测获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The coronavirus disease of 2019 (COVID-19) emerged as a global pandemic. Historically, the group of human coronaviruses can also affect the central nervous system leading to neurological symptoms; however, the causative mechanisms of the neurological manifestations of COVID-19 disease are not well known. Seizures have not been directly reported as a part of COVID-19 outside of patients with previously known brain injury or epilepsy. We report two cases of acute symptomatic seizures, in non-epileptic patients, associated with severe COVID-19 disease.

CASE PRESENTATIONS: Two advanced-age, non-epileptic, male patients presented to our northeast Ohio-based health system with concern for infection in Mid-March 2020. Both had a history of lung disease and during their hospitalization tested positive for SARS-CoV-2. They developed acute encephalopathy days into their hospitalization with clinical and electrographic seizures. Resolution of seizures was achieved with levetiracetam.

DISCUSSION: Patients with COVID-19 disease are at an elevated risk for seizures, and the mechanism of these seizures is likely multifactorial. Clinical (motor) seizures may not be readily detected in this population due to the expansive utilization of sedatives and paralytics for respiratory optimization strategies. Many of these patients are also not electrographically monitored for seizures due to limited resources, multifactorial risk for acute encephalopathy, and the risk of cross-contamination. Previously, several neurological symptoms were seen in patients with more advanced COVID-19 disease, and these were thought to be secondary to multi-system organ failure and/or disseminated intravascular coagulopathy-related brain injury. However, these patients may also have an advanced breakdown of the blood-brain barrier precipitated by pro-inflammatory cytokine reactions. The neurotropic effect and neuroinvasiveness of SARS-Coronavirus-2 have not been directly established.

CONCLUSIONS: Acute symptomatic seizures are possible in patients with COVID-19 disease. These seizures are likely multifactorial in origin, including cortical irritation due to blood-brain barrier breakdown, precipitated by the cytokine reaction as a part of the viral infection. Patients with clinical signs of seizures or otherwise unexplained encephalopathy may benefit from electroencephalography monitoring and/or empiric anti-epileptic therapy. Further studies are needed to elucidate the risk of seizures and benefit of monitoring in this population.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Hepburn M, Mullaguri N, George P, et al. Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is There an Association? Neurocrit Care. 2021. PMID: 32462412. doi:10.1007/s12028-020-01006-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。